{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T12:05:26Z","timestamp":1792325126127,"version":"4.4.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,4,18]],"date-time":"2015-04-18T00:00:00Z","timestamp":1429315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2015,4,18]],"date-time":"2015-04-18T00:00:00Z","timestamp":1429315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Positron emission tomography (PET)\/computed tomography (CT) using <jats:sup>68<\/jats:sup>Ga-labeled 1,4,7,10-tetraazacyclododecane-<jats:italic>N<\/jats:italic>,<jats:italic>N<\/jats:italic>\u2032,<jats:italic>N<\/jats:italic>\u2033,<jats:italic>N<\/jats:italic>\u2034-tetraacetic acid-<jats:sc>d<\/jats:sc>-Phe<jats:sup>1<\/jats:sup>-Tyr<jats:sup>3<\/jats:sup>-octreotide (DOTATOC) has been used to detect neuroendocrine tumors (NETs). The purpose of this study was to investigate the clinical efficacy of DOTATOC-PET\/CT for detecting clinically suspected NETs when conventional imaging modalities were negative or inconclusive, in terms of additional value.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A total of 46 patients were analyzed retrospectively. Among them, 14 patients underwent a DOTATOC-PET\/CT scan for detecting unknown primary tumors after histopathological confirmation of a NET at metastatic sites (group A): 7 patients for detecting metastasis or recurrence after surgery for NET because of their high hormone levels but with no recurrence detected by other imaging modalities (group B); the remaining 25 patients for detecting suspected NETs because their hormone levels were high with no history of histopathologically proven NET (group C). Additional information was assessed, according to each situation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In group A, unknown primary tumors were suspected by DOTATOC-PET\/CT in 8 of 14 patients (gastrointestinal\/pancreatic NET in 7 patients, prostatic cancer in 1 patient), but prostatic cancer was not confirmed by histopathology (i.e., false positive). In group B, DOTATOC-PET\/CT depicted lesions in six of seven patients, including nodal metastasis (<jats:italic>n<\/jats:italic>\u00a0=\u00a05) and liver metastasis (<jats:italic>n<\/jats:italic>\u00a0=\u00a01). In group C, DOTATOC-PET\/CT did not demonstrate any abnormal foci except in one case of pancreatic NET. Additional information was obtained in 50, 86, and 4\u00a0% of cases, in groups A, B, and C, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>DOTATOC-PET\/CT was useful for detecting NETs, especially when recurrence or metastases were suspected because of high hormone levels after surgery for a NET. It is unlikely, however, that additional information can be acquired in patients with no history of NET simply based on high hormone levels.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12149-015-0973-7","type":"journal-article","created":{"date-parts":[[2015,4,17]],"date-time":"2015-04-17T04:49:41Z","timestamp":1429246181000},"page":"512-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Additional information gained by positron emission tomography with 68Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors"],"prefix":"10.1007","volume":"29","author":[{"given":"Yuji","family":"Nakamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Ishimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Temma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Saji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,18]]},"reference":[{"key":"973_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejim.2013.06.012","volume":"25","author":"L Tagliabue","year":"2014","unstructured":"Tagliabue L, Del Sole A. Appropriate use of positron emission tomography with [(18)F]fluorodeoxyglucose for staging of oncology patients. Eur J Intern Med. 2014;25:6\u201311.","journal-title":"Eur J Intern Med"},{"key":"973_CR2","first-page":"225","volume":"49","author":"PF Rambaldi","year":"2005","unstructured":"Rambaldi PF, Cuccurullo V, Briganti V, Mansi L. The present and future role of (111)In pentetreotide in the PET era. Q J Nucl Med Mol Imaging. 2005;49:225\u201335.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"Suppl 2","key":"973_CR3","doi-asserted-by":"publisher","first-page":"42S","DOI":"10.2967\/jnumed.110.085753","volume":"52","author":"V Ambrosini","year":"2011","unstructured":"Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide imaging and therapy in Europe. J Nucl Med. 2011;52(Suppl 2):42S\u201355S.","journal-title":"J Nucl Med"},{"key":"973_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2967\/jnumed.106.035667","volume":"48","author":"M Gabriel","year":"2007","unstructured":"Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68 Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508\u201318.","journal-title":"J Nucl Med"},{"key":"973_CR5","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","volume":"52","author":"TD Poeppel","year":"2011","unstructured":"Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. 68 Ga-DOTATOC versus 68\u00a0Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864\u20137.","journal-title":"J Nucl Med"},{"key":"973_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/0284185113496679","volume":"55","author":"J Yang","year":"2014","unstructured":"Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol. 2014;55:389\u201398.","journal-title":"Acta Radiol"},{"key":"973_CR7","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00259-007-0450-1","volume":"34","author":"I Buchmann","year":"2007","unstructured":"Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Sch\u00e4fer M, et al. Comparison of 68\u00a0Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617\u201326.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"973_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00259-009-1205-y","volume":"37","author":"V Prasad","year":"2010","unstructured":"Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET\/CT. Eur J Nucl Med Mol Imaging. 2010;37:67\u201377.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"973_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/RLU.0b013e31823ea730","volume":"37","author":"N Naswa","year":"2012","unstructured":"Naswa N, Sharma P, Kumar A, Soundararajan R, Kumar R, Malhotra A, et al. 68Ga-DOTANOC PET\/CT in patients with carcinoma of unknown primary of neuroendocrine origin. Clin Nucl Med. 2012;37:245\u201351.","journal-title":"Clin Nucl Med"},{"key":"973_CR10","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s12149-014-0900-3","volume":"28","author":"K Kubota","year":"2014","unstructured":"Kubota K, Okasaki M, Minamimoto R, Miyata Y, Morooka M, Nakajima K, et al. Lesion-based analysis of (18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine tumors. Ann Nucl Med. 2014;28:1004\u201310.","journal-title":"Ann Nucl Med"},{"key":"973_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s00535-009-0194-8","volume":"45","author":"T Ito","year":"2010","unstructured":"Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45:234\u201343.","journal-title":"J Gastroenterol"},{"key":"973_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s00259-012-2309-3","volume":"40","author":"A Kroiss","year":"2013","unstructured":"Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68\u00a0Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET\/CT. Eur J Nucl Med Mol Imaging. 2013;40:514\u201323.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"973_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12020-012-9631-1","volume":"42","author":"G Treglia","year":"2012","unstructured":"Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET\/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine. 2012;42:80\u20137.","journal-title":"Endocrine"},{"key":"973_CR14","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1007\/s00259-013-2482-z","volume":"40","author":"H Geijer","year":"2013","unstructured":"Geijer H, Breimer LH. Somatostatin receptor PET\/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2013;40:1770\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"973_CR15","first-page":"2806","volume":"80","author":"JC Reubi","year":"1995","unstructured":"Reubi JC, Waser B, Schaer JC, Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab. 1995;80:2806\u201314.","journal-title":"J Clin Endocrinol Metab"},{"key":"973_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/pros.10121","volume":"53","author":"J Hansson","year":"2002","unstructured":"Hansson J, Bjartell A, Gadaleanu V, Dizeyi N, Abrahamsson PA. Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate. 2002;53:50\u20139.","journal-title":"Prostate"},{"key":"973_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12022-007-0014-8","volume":"18","author":"GM Portela-Gomes","year":"2007","unstructured":"Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, Janson ET. Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas\u2014predominance of receptor subtype 4. Endocr Pathol. 2007;18:79\u201385.","journal-title":"Endocr Pathol"},{"key":"973_CR18","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1007\/s00259-010-1512-3","volume":"37","author":"I Virgolini","year":"2010","unstructured":"Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET\/CT tumour imaging with 68 Ga-DOTA-conjugated peptides: 68 Ga-DOTA-TOC, 68 Ga-DOTA-NOC, 68 Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-015-0973-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-015-0973-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-015-0973-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-015-0973-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T10:38:24Z","timestamp":1630579104000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-015-0973-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,18]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["973"],"URL":"https:\/\/doi.org\/10.1007\/s12149-015-0973-7","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,18]]},"assertion":[{"value":"9 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}